RELEASE ex99.htm FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial rep
Monday, November 14, 2011 BiopharmaWatch Research 1 min read
Key Takeaway: CERTIFICATION OF INTERIM FILINGS
I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following:
Date: November 9, 2011
/s/ Brad Thompson Brad Thompson, PhD President and CEO
CERTIFICATION OF INTERIM FILINGS
I, Doug Ball, CFO of Oncolytics Biotec
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck
Full Press Release Details
CERTIFICATION OF INTERIM FILINGS
I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following:
Date: November 9, 2011
/s/ Brad Thompson
Brad Thompson, PhD
President and CEO
CERTIFICATION OF INTERIM FILINGS
I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: